Musculoskeletal disorders and bisphosphonates: a disproportionality analysis within the Spanish pharmacovigilance database

  1. Yuste Pérez, M.ª Teresa
  2. Escudero Pastor, Elisa 1
  3. Marín Carrillo, Pedro 1
  1. 1 Universidad de Murcia
    info

    Universidad de Murcia

    Murcia, España

    ROR https://ror.org/03p3aeb86

Journal:
Revista de Osteoporosis y Metabolismo Mineral

ISSN: 2173-2345,  1889-836X

Year of publication: 2025

Type: Article

DOI: 10.20960/REVOSTEOPOROSMETABMINER.00050 GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista de Osteoporosis y Metabolismo Mineral

Bibliographic References

  • Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, Van K, Hyun D. Osteoporosis: A Review of Treatment Options. P T. 2018; 43(2): 92–104.
  • 10.1016/j.mcna.2020.06.004
  • 10.1016/j.bone.2013.09.023
  • 10.1016/j.bone.2021.116289
  • 10.1016/j.bone.2020.115493
  • 10.1016/S0140-6736(21)02646-5
  • Ganesan K, Goyal A, Roane D. Bisphosphonate. 2023. Treasure Island (FL): StatPearls Publishing
  • EMA. Leaflet of Adrovance. https://www.ema.europa.eu/en/documents/product-information/adrovance-epar-product-information_en.pdf. Accessed 15 November 2023.
  • FDA. Technical specifications of Fosamax. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf. Accessed 22 July 2023
  • 10.1097/01.rhu.0000221796.06383.4e
  • Carvajal A, Martín Arias LH, Sáinz M, Escudero A, Fierro I, Sauzet O, Cornelius VR, Molokhia M. Carpal Tunnel Syndrome Associated with Oral Bisphosphonates. A Population-Based Cohort Study. Plos One. 2016; 11: e0146772.
  • Ozaras N, Rezvani A. Diffuse skeletal pain after administration of alendronate. Indian J Pharmacol. 2010; 42: 245-6.
  • Yemisci OU, Yalbuzdag SA, Karatas M. Risedronate-induced arthritis. J Clin Rheumatol. 2010; 16: 168-9.
  • Uğurlar M. Alendronate- and risedronate-induced acute polyarthritis. Osteoporos Int. 2016; 27: 3383-5.
  • Black DM, Delmas PD, Eastel R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-22.
  • Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373: 1253-63.
  • Álvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Martín-Arias LH. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and sentinel system. Eur J Clin Pharmacol. 1998; 54: 483-8.
  • Inman W. Assessment of drug safety problems. in Epidemiological issues in reported drug-induced illness. S.I. Gent M, Editor. Mc Master University Library Press: Honolulu (ON). 1996; 17-24.
  • Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA) Drug Saf. 1999; 20: 109-117.
  • Faillie J-L. Case–non-case studies: principle, methods, bias and interpretation. Therapies. 2019;74:225-32.
  • Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13(8): 519-23.